A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.

ABSTRACT:

Background

Bispecific antibody has garnered considerable attention in the recent years due to its impressive preliminary efficacy in hematological malignancies. For solid tumors, however, the main hindrance is the suppressive tumor microenvironment, which effectively impedes the activation of infiltrating T cells. Herein, we designed a bispecific antibody AP203 with high binding affinity to PD-L1 and CD137 and assessed its safety and anti-tumor efficacy, as well as explored the mechanism of action.

Methods

The optimal antibody binders against PD-L1 and CD137 were screened from the OmniMab phagemid library. The binding affinity of the constructed AP203 were evaluated using enzyme-linked immunosorbent assay (ELISA) and biolayer interferometry (BLI). T-cell stimulatory capacity

SUBMITTER: Huang PL 

PROVIDER: S-EPMC10210478 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature